Filing Flows › Agios Pharmaceuticals (AGIO) › Q2 2025
Agios Pharmaceuticals (AGIO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Agios Pharmaceuticals (AGIO) reported revenue of $12.5M for the second quarter 2025 (Q2 2025), +45% from a year earlier and +43% from the quarter before.
Agios Pharmaceuticals, Q2 2025: revenue $12.5M (+45% year over year), net loss $112M, operating cash flow −$77.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.5M | +43% | +45% |
| Operating profit | −$127M | — | — |
| Net earnings | −$112M | — | — |
| Operating cash flow | −$77.1M | — | — |
What changed
Revenue was $12.5M in Q2 2025, up 45% year over year and up 43% from the previous quarter.
Operating costs exceeded revenue by $127.1M, an operating margin of -1020.1%. Total costs grew 22% against revenue growth of 45%. The fastest-growing cost line was SG&A (+29%). The quarter ended with a net loss of $112.0M, wider than the previous quarter's $89.3M loss.
Operating cash flow was −$77.1M. Non-cash charges added back $14.7M of share-based compensation. Working capital and other items added $20.2M. Capital expenditures of $875K exceeded it, leaving free cash flow of −$78.0M.
Questions
What was Agios Pharmaceuticals' revenue in the second quarter 2025?
Agios Pharmaceuticals (AGIO) reported revenue of $12.5M for the second quarter 2025 (Q2 2025), +45% from a year earlier and +43% from the quarter before.